Drugs / PLOSARACETAM
PLOSARACETAM
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06278766 | Feb → Apr 2024 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05686980 | Jan → Mar 2023 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05199142 | Sep 2021 → Mar 2022 | subjective cognitive decline | Syndesi Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT05212116 | Sep 2021 → Mar 2022 | major depressive disorder | Syndesi Therapeutics | Withdrawn | No outcome recorded |
| Phase 1 | NCT05486195 | Mar → Jul 2019 | cognitive disorder | AbbVie | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT05771428 | Jun 2023 → Aug 2024 | Alzheimer disease | AbbVie | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLOSARACETAM | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314929 ↗ |
| Known as | ABBV-552 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05771428 ↗ |
| Known as | SDI-118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05212116 ↗ |
| Modality | Small molecule | “SDI-118 is a small molecule” PMID 36733374 ↗ Jan 2023 |
| Route | Oral | “SDI-118 capsule self-administered orally once daily (QD) for 17 days.” NCT05199142 ↗ |